SCD Fingerprints

Abstract

This invention relates to methods of testing, diagnosing, monitoring, prognostically stratifying and classifying disease, disorders and other medical conditions and physiological states through the detection and analysis of soluble CD antigens in a body fluid sample.

1 . A composition comprising a plurality of isolated ligands and a carrier, wherein said ligands comprise one or more ligands that specifically bind to a soluble CD (sCD) antigen selected from the group consisting of: sCD14, sCD30, sCD54, sCD117 and sCD130. 
     
     
         2 - 4 . (canceled) 
     
     
         5 . The composition of  claim 1 , wherein said soluble CD (sCD) antigen is sCD117. 
     
     
         6 . The composition of  claim 1 , wherein said composition comprises at least a first and a second soluble CD antigen wherein the first soluble CD (sCD) antigen is sCD117 and the second soluble CD antigen is selected from the group consisting of: sCD14, sCD30, sCD54 and sCD130. 
     
     
         7 . The composition of  claim 1 , wherein said composition comprises at least a first, a second and a third soluble CD antigen wherein the first soluble CD (sCD) antigen is sCD117, and the second and third soluble CD antigen is independently selected from the group consisting of sCD14, sCD30, sCD54 and sCD130. 
     
     
         8 . The composition of  claim 1 , wherein said composition comprises at least a first, a second, a third and a fourth soluble CD antigen wherein the first soluble CD (sCD) antigen is sCD117, and the second, third and fourth soluble CD antigen is each independently selected from the group consisting of: sCD14, sCD30, sCD54 and sCD130. 
     
     
         9 . The composition of  claim 1 , wherein said plurality of isolated ligands specifically binds sCD117, sCD14, sCD30, sCD54 and sCD130. 
     
     
         10 . The composition of  claim 1 , wherein said composition further comprises one or more isolated ligands each of which specifically binds to a sCD antigen selected from the group consisting of the soluble isoforms of the CD antigens listed in Table 43. 
     
     
         11 . The composition of  claim 1 , wherein said composition further comprises one or more isolated ligands that specifically binds to a sCD antigen selected from the group consisting of the soluble (secreted or shed) isoforms of the CD antigens listed in Table 44 and/or Table 45. 
     
     
         12 . The composition of  claim 1 , wherein said composition further comprises a ligand that specifically binds to a soluble Major Histocompatibility Complex (sMHC) class I antigen. 
     
     
         13 - 18 . (canceled) 
     
     
         19 . The composition of  claim 1 , wherein said composition further comprises one or more of the following: a ligand which selectively bind to a cytokine, a chemokine, a gene expression signature and a micro-RNA expression profile. 
     
     
         20 . The composition of  claim 1 , wherein one or more of said ligands comprises one or more antibody CDR regions. 
     
     
         21 . The composition of  claim 20 , wherein one or more of said ligands further comprises a non-immunoglobulin scaffold. 
     
     
         22 . The composition of  claim 21 , wherein said non-immunoglobulin scaffold is synthetic. 
     
     
         23 . The composition of  claim 21 , where said non-immunoglobulin scaffold is selected from the group consisting of CTLA4, fibronectin, lipocallin, Rbp, Bbp ApoD, a natural bacterial receptor, staphyloccocus A protein (SpA), GroEL, transferrin, tetranectin, human C-lectin, an AVIMER™ and an AFFIBODY™ scaffold. 
     
     
         24 . The composition of  claim 21 , wherein one or more of said ligands is an antibody. 
     
     
         25 . The composition of  claim 24 , wherein said antibody is selected from the group consisting of: a monoclonal antibody, an Fv, scFv, Fab, (Fab)2, an Fd, and a single domain antibody. 
     
     
         26 . The composition of  claim 1 , wherein said plurality of ligands is bound to a solid support. 
     
     
         27 . The composition of  claim 26 , wherein said solid support is planar. 
     
     
         28 . The composition of  claim 26 , wherein said solid support is selected from the group consisting of a bead, a chip, a glass surface, nitrocellulose, and an ELISA plate. 
     
     
         29 . The composition of  claim 26 , wherein said plurality of ligands bound to a solid support is formatted as an array. 
     
     
         30 - 72 . (canceled) 
     
     
         73 . The composition of  claim 1 , which additionally comprises a pharmaceutically acceptable carrier, excipient or stabilizer. 
     
     
         74 . A kit comprising the composition of  claim 1 .